Jatenzo Pill
Phase 2Small molecule
Jatenzo Pill is one of 34 small molecule programs targeting Chronic Kidney Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Aranesp
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Uloric
TakedaPreclinical
Lorelco
SanofiPreclinical
Sovaldi
GileadPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Genotropin
EMD SeronoPreclinical
Tradjenta
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Jatenzo Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSt. Louis University